Subcutaneous anti-TNF alfa induced sustained minimal disease activity and remission in psoriatic arthritis patients: a retrospective study
- 16 August 2016
- journal article
- research article
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 128 (7) , 693-696
Abstract
Objective: The aim of the present study was to assess the rate of sustained Minimal Disease Activity (MDA) and remission in a group of psoriatic arthritis (PsA) patients treated with TNFα blockers. Methods: We perform a retrospective study on our database of PsA patients treated with adalimumab, etanercept and golimumab, with a minimum of 12 months of follow up. Patients were considered in sustained MDA when they met at least 5/7 of the criteria previously defined for at least 12 months of follow up. DAS28-CRP < 2.6, DAPSA score ≤ 4 and patient global assessment (PGA) ≤ 20 mm were also evaluated as remission criteria. Concordance between the remission criteria and MDA was also performed. Results: Of the 81 patients treated with TNFα blockers, at baseline no patients were in MDA or had a DAPSA score ≤ 4, while 17 (20.9%) had a DAS28-CRP score < 2.6. PGA ≤ 20 was recorded in 6 patients (7%). Sustained MDA was achieved in 35 (43.2%) patients while sustained DAPSA, DAS28-CRP and PGA remission were obtained respectively in 19.7%, 35.8% and 44.4% of patients. No difference was found between the three anti-TNFα in respect to the probability of achieve MDA. Conclusions: In this retrospective study, sustained MDA was achieved in 43.2% of patients treated with TNFα blockers. Moreover, sustained remission was achieved in a consistent number of patients, configuring this as an achievable target for PsA patients.Keywords
This publication has 28 references indexed in Scilit:
- The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)Annals of the Rheumatic Diseases, 2013
- Patient Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA and OMERACT StudyThe Journal of Rheumatology, 2011
- Development of a preliminary composite disease activity index in psoriatic arthritisAnnals of the Rheumatic Diseases, 2011
- Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohortArthritis Care & Research, 2010
- Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial dataArthritis Care & Research, 2010
- Remission in Early Rheumatoid ArthritisThe Journal of Rheumatology, 2010
- Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritisAnnals of the Rheumatic Diseases, 2010
- Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatmentAnnals of the Rheumatic Diseases, 2010
- Adalimumab for long‐term treatment of psoriatic arthritis: Forty‐eight week data from the adalimumab effectiveness in psoriatic arthritis trialArthritis & Rheumatism, 2007
- Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progressionArthritis & Rheumatism, 2004